DynamiCure Doses First Patients in Phase 1 Clinical Trial of Lead Antibody Candidate DCBY02 in Advanced Cancers
November 08, 2022 11:11 ET
|
DynamiCure Biotechnology, LLC
The lead candidate from DynamiCure’s anti-CD93 program, DCBY02 targets a wide range of metastatic solid tumors Phase 1 trial aims to assess the safety and anti-tumor activity of the candidate in...
DynamiCure Announces Appointment of Industry Veteran Peter Lasky as its First Chief People Officer
September 20, 2022 08:35 ET
|
DynamiCure Biotechnology, LLC
WALTHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic...
DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical Development
August 22, 2022 08:35 ET
|
DynamiCure Biotechnology, LLC
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic...